ArticleClinical oral investigations2025
The synergistic effect of low-intensity focused ultrasound and tideglusib on odontogenic differentiation of human dental pulp stem cells.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding signaling crosstalk in pulpitis: pathogenesis and precision therapeutics.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesThis study investigates the synergistic effects of Tideglusib, a GSK-3 inhibitor, and low-intensity focused ultrasound (LIFU) on the proliferation and odontogenic differentiation of human dental pulp stem cells (DPSCs) and lipopolysaccharide (LPS)-induced inflammatory DPSCs (LPS-DPSCs). MATERIALS AND
methodsDPSCs were exposed to Tideglusib (100, 250, and 500 nM) and LIFU (250 kHz, 2.5 W and 5 W for 60s and 120s). Cell proliferation was evaluated using acid phosphatase (APH) assay, and optimal parameters were determined as 100 nM Tideglusib and LIFU (5 W) at 60s, 120s, 60s/100 nM, and 120s/100 nM. Inflammatory conditions were induced using LPS. Cell proliferation was assessed using APH assay and confocal laser scanning microscope (CLSM), while odontogenic differentiation was evaluated via Alizarin red staining, wound healing assay, and qRT-PCR targeting odontogenic markers (RUNX2, ALPL, BMP2, DMP1), Wnt pathway activation (AXIN2), pro-apoptotic (CASP3), and anti-apoptotic (BCL2L1) genes.
resultsThe combination of LIFU and tideglusib (5 W 120s/100 nM) significantly enhanced (p < 0.05) proliferation, mineralization, and wound closure in both DPSC and LPS-DPSC groups. CLSM confirmed increased cell density, corroborating the APH assay, and qRT-PCR revealed upregulation of odontogenic and Wnt signalling markers. In LPS-DPSCs, CASP3 was downregulated and BCL2L1 upregulated, indicating improved cell survival in an inflammatory microenvironment.
conclusionsThe synergistic use of LIFU and Tideglusib promotes DPSC proliferation, migration, wound closure, and odontogenic differentiation, even under inflammatory stress. CLINICAL RELEVANCE: This pharmacomechanical approach offers a minimally invasive, biologically driven strategy for regenerative endodontic therapy, with strong translational potential in managing reversible pulpitis and promoting dentine repair.
Indexed as
Identifiers
41134403What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.